Biotie Therapies Oyj

Type: Company
Name: Biotie Therapies Oyj (Biotie Therapies Corp)
First reported 15 hours ago - Updated 14 hours ago - 2 reports

BRIEF-Biotie Therapies Oyj - Selincro enters the market in Spain

7:06am BSTJuly 22 (Reuters) - Biotie Therapies Oyj : * Its partner H.Lundbeck A/S brought Selincro on the market in Spain * Says is eligible for a milestone payment of EUR 2 million related to themarket entry * Source text for Eikon * Further company ... [Published Reuters UK - 14 hours ago]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Biotie Therapies Selects Bracket's CDR System(TM) for Phase 2 Trial of Treatment of Parkinson's Disease

Cognitive function is primary endpointCOPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, ... [Published Scottrade - Jul 18 2014]
First reported Jul 16 2014 - Updated Jul 16 2014 - 4 reports

Biotie Therapies Selects Bracket's CDR System for Phase II Parkinson's Trial

Bracket announced that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected its CDR System for use as the primary endpoint for their Phase II trial of SYN120, an orally ... [Published Applied Clinical Trials - Jul 16 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 2 reports

Michael J. Fox Foundation Awards Biotie $2M

Biotie Therapies has signed a $2M research contract with The Michael J. Fox Foundation to investigate SYN120 in Parkinson's disease patients with dementia. ... [Published Technology Networks - Jul 14 2014]
First reported Jul 14 2014 - Updated Jul 14 2014 - 1 reports

Biotie passes up on option to acquire Neurelis

Finland-based biotech firm Biotie Therapies (Nasdaq-OMX; BTH1V) said on Friday that it has decided not to exercise its exclusive option to acquire Neurelis, a private US specialty pharmaceutical company, under a deal signed last year (The Pharma Letter ... [Published Pharma Letter - Jul 14 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 6 reports

Neurelis reclaims rights to epilepsy drug from Biotie

Encinitas-based Neurelis Inc. entered an agreement with Biotie Therapies Corp. to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development of intranasal diazepam (NRL-1) for pediatric and adult ... [Published San Diego Daily Transcript - Jul 11 2014]
First reported Jul 11 2014 - Updated Jul 11 2014 - 1 reports

Michael J. Fox foundation grants Biotie $2 million

Finnish biotech company Biotie has received two million dollars (1.5 million euros) from a foundation set up by Hollywood star Michael J. Fox.Biotie focuses on products for neurodegenerative and psychiatric disorders. It will use the money to see if ... [Published Good News From Finland - Jul 11 2014]
First reported Jul 10 2014 - Updated Jul 10 2014 - 3 reports

Biotie: Selincro receives positive draft guidan...

Biotie: Selincro receives positive draft guidance from UK's NICE ... [Published MoneyAM - Jul 10 2014]
First reported Jul 08 2014 - Updated Jul 09 2014 - 2 reports

Biotie awarded USD 2 million grant from The Michael J. Fox Foundation

09-07-2014: Biotie Therapies has signed a USD 2 million research contract with The Michael J. Fox Foundation (MJFF) to investigate SYN120 in Parkinson's disease patients with dementia. SYN120 is a dual antagonist of 5-HT6 and 5-HT2a receptors and these ... [Published Bionity.com - Jul 09 2014]
First reported Jul 08 2014 - Updated Jul 08 2014 - 3 reports

BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In /i>

7/8/2014 6:11:09 AMTURKU, Finland, July 8, 2014 (GLOBE NEWSWIRE) -- Biotie announces that full data from the positive Phase 2b study evaluating tozadenant, an adenosine A2a antagonist, in Parkinson's disease patients experiencing end of dose wearing off ... [Published BioSpace - Jul 08 2014]
First reported Jul 03 2014 - Updated Jul 03 2014 - 1 reports

BIOTIE THERAPIES : Smarter Microwave Peptide Synthesis in Motion

A short video demonstrating the capabilities of Biotage® Initiator+ Alstra™, a fully automated microwave peptide synthesizer, is released today on the biotage.com website. The video gives an impression of the system's robotic precision as well as an overview ... [Published 4 Traders - Jul 03 2014]
First reported Jul 01 2014 - Updated Jul 01 2014 - 1 reports

BIOTIE THERAPIES : New Application: Effective Extraction of Vitamin D Metabolites Utilizing ISOLUTE® SLE+

React to this article Latest news on BIOTIE THERAPIES OYJDuration :Period : ... [Published 4 Traders - Jul 01 2014]

Quotes

...in the various dementias, and also to serve as an instrument to definitively measure the benefits of treatment, " said Professor Keith Wesnes. "I'm delighted that Biotie has selected the CDR System for this very important trial."
Transparency Market Research includes new marketmarket research report "U SS Commercial Air Conditioning Systems (VRF) Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to its huge collection of research reports. Browse the full report: http://www.transparencymarketresearch
Sponsored by: "Parkinson's Disease affects over one million families and when I developed the CDR System over 20 years ago, it was with the intention of making a real impact in drug development, and eventually, in people's lives" said Professor Keith Wesnes. "I'm very pleased that Biotie has selected the CDR System for this very important trial."
Timo Veromaa, president and chief executive of Biotie, said: "Following the return of full global rights of tozadenant to Biotie in March 2014 we have now decided not to pursue further development of NRL-1 and wish Neurelis success with this important product. Biotie remains committed to starting Phase III with tozadenant in Parkinson's disease in the first half of 2015, and we look forward to the start of Phase II studies for SYN120 in Parkinson's disease dementia and BTT-1023 for primary sclerosing cholangitis by the end of 2014, and delivering top-line data from the ongoing Phase II study with nepicastat in cocaine dependence, also around end 2014."

More Content

All (59) | News (37) | Reports (0) | Blogs (3) | Audio/Video (0) | Fact Sheets (1) | Press Releases (18)
sort by: Date | Relevance
Biotie: Selincro enters the market in Spain [Published GlobeNewswire: Advertising News - 14 hours ago]
BRIEF-Biotie Therapies Oyj - Selincro enters th... [Published Reuters UK - 14 hours ago]
Biotie: Selincro enters the market in Spain [Published GlobeNewswire: Acquisitions News - 15 hours ago]
Biotie: Selincro enters the market in Spain [Published Street Sweeper - 15 hours ago]
Biotie Therapies Selects Bracket's CDR System(T... [Published Scottrade - Jul 18 2014]
Biotie Therapies Selects Bracket's CDR System f... [Published Applied Clinical Trials - Jul 16 2014]
Biotie Therapies Selects Bracket"s CDR System(T... [Published Presskontakt.se - Jul 16 2014]
Biotie Therapies Selects Bracket's CDR System™... [Published TickerTech.com - Jul 16 2014]
Biotie Therapies Selects Bracket's CDR System™ ... [Published PR Newswire: Health - Jul 16 2014]
Michael J. Fox Foundation Awards Biotie $2M [Published Technology Networks - Jul 14 2014]
Michael J Fox Foundation to finance Parkinson's... [Published Manufacturing Chemist - Jul 14 2014]
Biotie passes up on option to acquire Neurelis [Published Pharma Letter - Jul 14 2014]
Michael J. Fox Foundation Awards $2 Million for... [Published Philanthropy News Digest - Jul 13 2014]
Neurelis reclaims rights to epilepsy drug from ... [Published San Diego Daily Transcript - Jul 11 2014]
Biotie decides not to take advantage of exclusi... [Published PredictWallStreet - Jul 11 2014]
Neurelis Regains Rights to Intranasal Diazepam ... [Published Digital Journal - Jul 11 2014]
Neurelis Regains Rights to Intranasal Diazepam ... [Published CEOWorld Magazine - Jul 11 2014]
Neurelis Regains Rights to Intranasal Diazepam ... [Published PR Newswire: Health - Jul 11 2014]
Biotie Says Not To Exercise Option To Buy Neure... [Published RTTNews.com - Jul 11 2014]
Michael J. Fox foundation grants Biotie $2 million [Published Good News From Finland - Jul 11 2014]
UK’s NICE backs Lundbeck drug for alcohol depen... [Published Pharma Letter - Jul 10 2014]
Biotie: Selincro receives positive draft guidan... [Published GlobeNewswire: Advertising News - Jul 10 2014]
Biotie: Selincro receives positive draft guidan... [Published MoneyAM - Jul 10 2014]
Biotie: Selincro receives positive draft guidan... [Published GlobeNewswire: Acquisitions News - Jul 10 2014]
Biotie: Selincro receives positive draft guidan... [Published Stock Nod - Jul 10 2014]
Biotie: Selincro receives positive draft guidan... [Published EuroInvestor - Jul 10 2014]
Biotie awarded USD 2 million grant from The Mic... [Published Bionity.com - Jul 09 2014]
MJ FF to fund clinical trial involving Parkinso... [Published Examiner.com - Jul 09 2014]
Biotie awarded USD 2 million grant from The Mic... [Published Noodls - Jul 08 2014]
BioTie Therapies Corp.: Tozadenant Phase 2b Par... [Published BioSpace - Jul 08 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Biotie Therapies Selects Bracket's CDR System™ ... [Published PR Newswire: Health - Jul 16 2014]
COPENHAGEN, Denmark, July 16, 2014 /PRNewswire/ -- Bracket is pleased to announce that Biotie Therapies, a specialized drug development company focusing on products for neurodegenerative and psychiatric disorders, has selected the CDR System for use as ...
Neurelis Regains Rights to Intranasal Diazepam ... [Published PR Newswire: Health - Jul 11 2014]
SAN DIEGO, July 11, 2014 /PRNewswire/ -- Neurelis, Inc. ("Neurelis") today announced an agreement with Biotie Therapies Corp. ("Biotie") to end the option held by Biotie to purchase Neurelis, clearing the way for Neurelis to commence further development ...
Research and Markets: Tozadenant by Biotie (Par... [Published Business Wire Health News - May 19 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/3f224r/tozadenant) has announced the addition of the "Tozadenant (Parkinson's Disease) - Forecast and Market Analysis to 2022" report to their offering. Tozadenant ...
1

Press Releases

sort by: Date | Relevance
Biotie: Selincro enters the market in Spain [Published GlobeNewswire: Advertising News - 14 hours ago]
Biotie: Selincro enters the market in Spain [Published GlobeNewswire: Acquisitions News - 15 hours ago]
Biotie: Selincro receives positive draft guidan... [Published GlobeNewswire: Advertising News - Jul 10 2014]
Biotie: Selincro receives positive draft guidan... [Published GlobeNewswire: Acquisitions News - Jul 10 2014]
Biotie: Tozadenant Phase 2b Parkinson's disease... [Published GlobeNewswire: Advertising News - Jul 08 2014]
1 2 3 4
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.